How is the pharmaceutical industry in China developing now? What is the breakthrough in the field of advanced technology at present?

Major listed companies in the biomedical industry: At present, the listed companies in the biomedical industry in China mainly include Tiantan Bio (600 16 1), Hualan Bio (002007), Zhifei Bio (300 122), Kangtai Bio (30060 1) and Kangtai Bio. The core data of this paper: R&D expenditure, the number of new drugs applied for listing, and the monthly cumulative growth of biomedical R&D expenditure in China. With the steady progress of medical reform, the traditional sales-oriented expansion model is unsustainable, and domestic pharmaceutical companies are facing innovative transformation. From 20 16 to 2020, r&; Investment will continue to expand. In 2020, the R&D expenditure of biomedical listed companies in China reached1153.4 billion yuan, a year-on-year increase of 37. 10%. In the first half of 20021,the R&D expenditure of listed biomedical companies in China has reached 6.978 billion yuan, and it is expected that the R&D expenditure will further increase throughout the year. Generally speaking, R&; D the increase of investment will help to accelerate the transformation of research results of biomedical products to a certain extent. China's new drug application and listing situation is optimistic, and new product research and development is active. Judging from the transformation results, the listing situation of new drugs in China is optimistic. From 2017 to 2020, the number of new drug applications and listings in China fluctuated greatly, with 45 cases reaching the peak in 20 18. In 20 19, the center for drug evaluation accepted 25 applications (16 varieties) for the listing of China innovative drugs, and 43 applications were listed in 2020. Note: Innovative drugs refer to drugs that are original by enterprises or research institutions, have new chemical structures and new therapeutic uses, and have independent intellectual property patents. They have significant curative effects on specific diseases, improve the treatment rate and prolong the survival time of patients. Judging from the activities, domestic biopharmaceutical companies are in R&; D is active. Due to the outbreak of COVID-19 in 2020, three pharmaceutical companies invested in R&D in COVID-19. Vaccines and test reagents. In addition, pharmaceutical companies focus on vaccines and immunoglobulins for human use. China's innovative drug research and development ability is strong, and its input and output need to be improved. Although R & ampd is in the biomedical industry in China; D input and achievement transformation are optimistic, but compared with developed countries, China's innovative drug research and development still needs to be improved in many indicators. At R & ampd China has a certain gap with developed countries in terms of input capacity and output. Even compared with India at a similar level, there is a certain gap in the investment in new drug research and development. At present, the Chinese government pays more and more attention to the research and development of innovative drugs with independent intellectual property rights, and has issued a series of incentive policies, which have achieved certain results. However, in order to continuously improve the research and development ability of innovative drugs in China, the Chinese government should constantly adjust and improve relevant policies to create a good policy environment for the research and development of innovative drugs in Chinese pharmaceutical enterprises. Note: strong: ★★, strong: ★★☆, general: ★★, weak: ★☆, weak: ★, not counting:-r&; Innovative drugs in China; D trend Although China's current R&; There is still a gap between Class D and the world's leading countries, but in view of China's leading position and huge market in the global pharmaceutical outsourcing industry, China has the strength to become a global drug innovation center in the future; And with the increasing popularity of China COVID-19 vaccine in the world, the national plan attaches great importance to biomedicine, and China's biomedical industry is expected to develop innovative drugs in the future. The above data refer to the Analysis Report on the Market Prospect and Investment Strategic Planning of Biomedical Industry in China by Prospective Industry Research Institute.

Now Chinese medicine is developing very well, especially in developing Chinese medicine industry. The slogan now is to revitalize Chinese medicine. If you can enter this industry, it is also very good.

Six trends in the development of pharmaceutical industry-competition in Chinese patent medicine market will intensify; The life cycle of prescription drugs will be shortened; The third terminal market will be more active; The pharmaceutical market is further concentrated, and the polarization of medicine is further highlighted; Policy price cuts will continue; Structural adjustment will be further accelerated, and the variety structure of the enterprise market will undergo great changes. This report is divided into seventeen chapters. Firstly, the development of international and domestic pharmaceutical industry is introduced. Then the development of biopharmaceuticals, traditional Chinese medicine and chemicals is analyzed in detail. Then, the economic data of the pharmaceutical industry are analyzed. Then it introduces the development of OTC drug market, rural drug market in China and pharmaceutical industry in major areas of China. This paper analyzes the key enterprises in the pharmaceutical industry, pharmaceutical circulation, mergers and acquisitions, information construction and intellectual property protection. Finally, the competition pattern and investment of the pharmaceutical industry are analyzed, and the development prospect of the pharmaceutical industry is predicted scientifically. If you want to have a systematic understanding of the pharmaceutical industry or want to invest in the pharmaceutical industry, this report is an indispensable tool for you. After the policy "cold snap" in 2006, the prosperity of China pharmaceutical industry began to pick up in the first quarter of this year. Sales revenue and net profit were significantly higher than the same period of last year, and the gross profit margin of sales also increased year-on-year, which made a good start for the performance growth of pharmaceutical companies in the first half of this year. Experts in the industry pointed out that with the gradual implementation of the overall medical system reform, the amount of funds for medical services will continue to increase, which will inevitably lead to an increase in drug demand and the economic situation of the pharmaceutical industry will gradually "pick up". However, it can not be ignored that: D's overall strength is insufficient, and the homogenization competition is obvious. Although the investment income of some pharmaceutical companies contributed a lot to their net profit growth in the first quarter of this year, there is great uncertainty in this part of income.

China's pharmaceutical industry is still developing rapidly, and the development of traditional Chinese medicine is better and more distinctive, with good prospects.

I am in the pharmaceutical industry. At present, China's pharmaceutical industry is developing well. China's policies, economy, society and technology are all contributing to the development of China's pharmaceutical industry. Technological innovation is the general trend and the key to success. For example, Beizhengkang biological nano-selenium preparation has overcome the technical difficulties of nano-selenium layer, and the products are fresh and unique. Such a good product is very popular in the market.